Evidence map›Paper›PMID 39836489›Full record

ArticleClinical and experimental immunology2025

Functional validation of a novel STAT3 'variant of unknown significance' identifies a new case of STAT3 GOF syndrome and reveals broad immune cell defects.

Joseph Mackie, Daniel Suan, Peter McNaughton, Filomeen Haerynck, Michael O'Sullivan, Antoine Guerin, Cindy S Ma, Stuart G Tangye

Abstract readCase Reports
In one paragraph

Article in Clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Human CD21Journal of human immunity · 2026
    Review
  3. T follicular helper cells in primary immune regulatory disorders.The Journal of allergy and clinical immunology · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joseph MackieGarvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Daniel SuanGarvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Peter McNaughtonClinical Immunogenomics Research Consortium of Australasia (CIRCA), Darlinghurst, NSW, Australia.
Filomeen HaerynckDepartment of Pediatric Pulmonology, Infectious Diseases and Immunology, Ghent University Hospital, Ghent, Belgium.
Michael O'SullivanClinical Immunogenomics Research Consortium of Australasia (CIRCA), Darlinghurst, NSW, Australia.
Antoine GuerinGarvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Cindy S MaGarvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Stuart G TangyeGarvan Institute of Medical Research, Darlinghurst, NSW, Australia.ORCID 0000-0002-5360-5180

Funding

American Association of ImmunologistsCareers in Immunology FellowshipNational Health and Medical Research Council of Australia 1176665Scheinberg Fellowship
6 · The paper itself

Abstract

introductionSignal transducer and activator of transcription 3 (STAT3) orchestrates crucial immune responses through its pleiotropic functions as a transcription factor. Patients with germline monoallelic dominant negative or hypermorphic STAT3 variants, who present with immunodeficiency and/or immune dysregulation, have revealed the importance of balanced STAT3 signaling in lymphocyte differentiation and function, and immune homeostasis. Here, we report a novel missense variant of unknown significance in the DNA-binding domain of STAT3 in a patient who experienced hypogammaglobulinemia, lymphadenopathy, hepatosplenomegaly, immune thrombocytopenia, eczema, and enteropathy over a 35-year period.

methodsIn vitro demonstration of prolonged STAT3 activation due to delayed dephosphorylation, and enhanced transcriptional activity, confirmed this to be a novel pathogenic STAT3 gain-of-function variant. Peripheral blood lymphocytes from this patient, and patients with confirmed STAT3 Gain-of-function Syndrome, were collected to investigate mechanisms of disease pathogenesis.

resultsB cell dysregulation was evidenced by a loss of class-switched memory B cells and a significantly expanded CD19hiCD21lo B cell population, likely influenced by a skewed CXCR3+ TFH population. Interestingly, unlike STAT3 dominant negative variants, cytokine secretion by activated peripheral blood STAT3 GOF CD4+ T cells and frequencies of Treg cells were intact, suggesting CD4+ T cell dysregulation likely occurs at sites of disease rather than the periphery.

conclusionThis study provides an in-depth case study in confirming a STAT3 gain-of-function variant and identifies lymphocyte dysregulation in the peripheral blood of patients with STAT3 gain-of-function syndrome. Identifying cellular biomarkers of disease provides a flow cytometric-based screen to guide validation of additional novel STAT3 gain-of-function variants as well as provide insights into putative mechanisms of disease pathogenesis.

Indexed as

Gain of Function MutationSTAT3 Transcription FactorAgammaglobulinemiaB-LymphocytesHumansMutation, MissenseReceptors, CXCR3T Follicular Helper CellsCXCR3 protein, humanReceptors, CXCR3STAT3 protein, humanSTAT3 Transcription Factorautoimmunityhypogammaglobulinemiaimmunodeficiencyimmuno-dysregulationimmunogenetics

Identifiers

PMID39836489
PMCPMC11791529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.